SAN DIEGO, Nov. 18, 2010 /PRNewswire/ — Aethlon Medical, Inc.
(OTC Bulletin Board:
AEMD), the pioneer in developing therapeutic filtration devices
to address infectious disease and cancer, disclosed today that it
has released a report entitled: “A Platform to Address
Bioterrorism.” The report is available on the company’s
website at:
http://www.aethlonmedical.com/knowledge-center/special-reports/
Or on SlideShare at:
www.slideshare.net/Aethlon/a-platform-technology-to-address-bioterrorism
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
(Photo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
About Aethlon MedicalAt Aethlon Medical, we create
revolutionary devices to address infectious disease and cancer. Our
devices are designed to be novel platform solutions that fill
therapeutic voids or aid in disease diagnosis and
monitoring.
Our Hemopurifier® is the first medical device to
selectively target the removal of infectious viruses and
immunosuppressive proteins from the entire circulatory system. We
recently discovered that our Hemopurifier® captures
tumor-secreted exosomes that suppress the immune system of those
afflicted with cancer. Prior to this discovery, a therapeutic
strategy to directly inhibit or reverse the immunosuppressive
destruction caused by exosomes did not exist in cancer care. By
eliminating this mechanism, we believe our Hemopurifier® can
fill an unmet clinical need and provide the benefit of an
immune-based therapy without adding drug toxicity
‘/>”/>
